To the Editor, The case report byYamaguchi et al. published on line ahead of print on November 14, 2013 in the Journal [5] about an 11year-old boy with attention-deficit/hyperactivity disorder (ADHD) treated for 2 years with atomoxetine, who suffered Takotsubo syndrome (TTS), implicating this drug, is of interest to clinicians managing patients with ADHD and for a possible TTS pathophysiological connotation. Atomoxetine, as the authors state, is a noncentral nerve-stimulating agent blocking reuptake of noradrenalin, and, as such, it can lead to cardiac responses similar to the ones resulting from intense efferent autonomic cardiac sympathetic nerve stimulation [2]. The pathophysiology of TTS is still elusive, but the currently prevailing theory implicates high catecholamines (both epinephrine and norepinephrine) as mediators for the resulting cardiomyocyte toxicity/injury [1, 3, 4]. There is a variation in the opinion about the exact pathomechanism in the sense that it is believed that either blood-borne catecholamines, resulting from the “spillover” from the autonomic cardiac sympathetic nerve terminals and the adrenal secretion [1, 3, 4]; or norepinephrine secreted locally by the autonomic cardiac sympathetic nerve terminals [2] is causing the cardiomyocyte toxicity/ injury. The clinical picture of the patient in this report, showing initially tachycardia and hypotension and subsequently bradycardia, electrocardiogram (ECG) T wave inversions, QTc interval prolongations, and multiple premature ventricular contractions, is exactly what has been described in human experiences and animal experiments, as a result of autonomic cardiac sympathetic nerve hyperactivity [2]. The fact that these injurious effects on the heart were not prevented by adrenalectomy in animal models of TTS [2] supports the primacy of the direct sympathetic cardiac nerve hyperactivity, with its local consequences (norepinephrine release) on the cardiomyocytes as opposed to blood-borne catecholamines as the mediator for the TTS phenotype. While this remains to be settled in the future, pediatricians and psychiatrists should be vigilant in monitoring their patients with ADHD treated with atomoxetine for a possible adverse effect of this drug with a similar outcome as the one in this reported case. Accordingly, hypertension, tachycardia, and extrasystoles, evaluated during history taking and physical examination, most probably, should be considered as harbingers of a possible impending attack of TTS, since the ECGmanifestations (ST elevations, T wave inversions, bradycardia, and QTc prolongation) are manifested after the disease is already in progress. However, recording an ECG, as the authors advise [5], to evaluate whether a child has a prolonged QTc syndrome before the initiation of therapy with atomoxetine or before an increase of its dose is sensible.